PharmaTelevision - Naiyin Wang explains Shanghai Fosun Pharma's strengths and advantages over other pharma companies in China

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Naiyin Wang explains Shanghai Fosun Pharma's strengths and advantages over other pharma companies in China

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Naiyin Wang, Investment Director at Shanghai Fosun Pharma

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fosun's focus and activities in China

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BioTrinity 2011. On this show I have Naiyin Wang, who is the Investment Director at a company called Shanghai Fosun Pharmaceutical and you are based here in London, welcome to the show.

Naiyin Wang:

Thank you.

Fintan Walton:

Let's first of all before we got to Shanghai Fosun Pharmaceutical let's just look at the Fosun company, because that's obviously a Shanghai based company?

Naiyin Wang:

Yes, well Shanghai Fosun started as a diagnostic company in '92,and in '94 became Fosun Pharma getting into the pharmaceutical business by '98 listed in our Shanghai exchange, and after that the Fosun Group's developed this kind of the investment IPO and now we have the Fosun International is in real estate, mining, steel. We have a brokerage, we have a joint venture with Prudential Financial of US of life insurance in China so that's kind a diversified interestingly, but for Fosun Pharmaceutical itself is still very much focused on the pharmaceutical side, we are we own every aspect of a healthcare in China. We are in manufacturing larger molecule, small molecule, we are in diagnostic, we also own 49% of Sinopharm which is number one distributor in China is larger than number two and number three put together. We are also in high end healthcare we are providing service we have a joint venture with the company called Chindex which is NASDAQ listed company. We have a very good brand name hospital called United Family Hospital which we intend to with this joint venture to expand it out throughout the China.

Fintan Walton:

Okay, so you are quite even within Shanghai Fosun Pharmaceutical you are quite diversified in your activities?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Naiyin Wang

Investment Director

Naiyin Wang currently works as Investment Director at Shanghai Fosun Pharma. Naiyin Wang is trained as a medicinal chemist in China; Received PhD in molecular biology at Imperial College in London. Worked as researcher in many different disciplines. Gained commercial experiences by sales of chemicals including APIs and promoting packaging services from china to European companies; As part of team, try to raise fund for a 3D imaging device; Formed a company to do the technology transfer to Chinese pharmaceutical companies in the area of Biotechnology. Now, works as the investment director and chief representative of the Shanghai Fosun Pharmaceutical in London office.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Shanghai Fosun Pharma

Shanghai Fosun Pharmaceutical (Group) Co., Ltd is a China-based company engaged in research, development, production, distribution and retailing of medical products. The Company's principal products are pharmaceuticals for malarias, such as Artesunate Tablets; pharmaceuticals for liver inflammations, such as Atomolan; pharmaceuticals for female diseases, such as Huahong Tablets, as well as pharmaceuticals for diabetes , such as insulin injection. The Company also provides pharmaceuticals for cardiovascular diseases , antineoplastic drugs, pharmaceuticals for sick disease, pediatrics drugs and gastrointestinal tract drugs, among others. The Company also operates regular chain drug stores. It distributes its products primarily in domestic and overseas markets.